Skip to content
Our Impact

What your support has discovered.

21
milestone papers
20
years of research
81%
of gifts to research
Section 01Twenty years, in order

Milestones by year

  1. 2006

    One milestone

    Experimental Neurology

    1. Your earliest support funded the discovery that started it all: BMAA, a toxin produced by cyanobacteria (blue-green algae), directly injures motor neurons. This was the first hard evidence connecting an environmental toxin to the disease process behind ALS.

      Experimental Neurology, 201: 244–252
  2. 2008

    One milestone

    Environmental Microbiology

    1. Follow-up research found the same toxin in reservoirs across the UK, providing evidence for much greater environmental exposure than previously thought.

      Environmental Microbiology, 10(3): 702–708
  3. 2009

    One milestone

    Amyotrophic Lateral Sclerosis

    1. Your support helped establish the link between BMAA exposure and elevated ALS rates in Gulf War veterans, one of the clearest human populations pointing to an environmental trigger.

      Amyotrophic Lateral Sclerosis, 10 (Suppl 2): 109–117
  4. 2013

    One milestone

    PLOS ONE

    1. A pivotal discovery: BMAA can mistakenly be built into human proteins leading to cell death, which can be prevented by L-serine.

      PLOS ONE, 8(9): e75376
  5. 2016

    Two milestones

    Proceedings of the Royal Society B · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

    1. Your support helped show BMAA can trigger the same brain changes seen in Alzheimer's disease, extending the toxin's reach beyond ALS.

      Proceedings of the Royal Society B, 283: 20152397
    2. Building on that discovery, we launched a Phase I clinical trial testing L-serine in ALS patients. L-serine supplementation slowed ALS disease progression by up to 85%, marking the first evidence that L-serine might be an effective therapy to treat ALS.

      Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  6. 2019

    One milestone

    PLOS ONE

    1. Stranded dolphins in Florida were the first animals found with detectable BMAA in their brains alongside Alzheimer's- and ALS-like brain damage, providing a direct link between BMAA and neurodegenerative diseases.

      PLOS ONE: Cyanobacterial neurotoxin BMAA and brain pathology in stranded dolphins
  7. 2020

    Two milestones

    Journal of Neuropathology and Experimental Neurology · Open Biology

    1. L-serine was shown to reduce ALS symptoms in an animal model, and BMAA was shown to trigger those same symptoms, closing the loop between cause and possible treatment.

      Journal of Neuropathology and Experimental Neurology, nlaa002
    2. Your support helped identify eight distinct blood markers that reliably tell ALS patients apart from healthy people using a simple blood draw. This is the first step towards a rapid and accurate ALS biomarker test.

      Open Biology, 10: 200116
  8. 2021

    One milestone

    Neurotoxicity Research

    1. Your funding helped establish the link between algal bloom toxins and human and animal brain disease, building the case that ALS may be preventable, not just treatable.

      Neurotoxicity Research, 39: 27–35
  9. 2022

    Four milestones

    Journal of the Neurological Sciences · PLOS ONE · Phase II clinical trial · Journal of Natural Products

    1. The high sensitivity of the ALS blood biomarker held up in a larger and more diverse group of participants, bringing this innovation one step closer to helping patients.

      Journal of the Neurological Sciences, 442: 120396
    2. The same research approach advancing our ALS biomarker test showed promise for Alzheimer's too, pointing to a possible blood test for earlier detection.

      PLOS ONE, 17(4): e0267407
    3. Establishment of L-serine as a neuroprotective molecule led us to initiate a Phase II clinical trial testing L-serine in patients with Mild Cognitive Impairment at Houston Methodist Hospital. This is true translational research, moving L-serine from the bench to the bedside. Trial results should be available in 2027.

      Phase II clinical trial, Houston Methodist Hospital

    4. Cyclotides, a class of plant peptides found in violets, showed early promise as a partner therapy for one of the deadliest brain cancers, glioblastoma. This promising new avenue of research provides hope for patients where few effective therapies exist.

      Journal of Natural Products, 85(1): 34–46
  10. 2023

    Two milestones

    Toxins · Toxicology Reports

    1. Your support helped detect BMAA in the air itself around the Great Salt Lake, not just the water, raising new questions about how people are exposed.

      Toxins, 15(11): 659
    2. BMAA was identified in the nasal pathways of Alzheimer's patients, reinforcing contaminated air as a risk factor and identifying a route for exposure that gives direct access to the brain.

      Toxicology Reports, 10: 87–96
  11. 2024

    Two milestones

    Biomedicines · Brain Communications

    1. Follow-up research confirmed cyclotides' potential to strengthen glioblastoma treatment, each study building the case for a therapy patients sorely need.

      Biomedicines, 12(10): 2216
    2. With more data behind it, the ALS biomarker test moved closer to a stage where doctors can use it as a complementary tool to aid in diagnoses.

      Brain Communications, 6(5): fcae268
  12. 2025

    Two milestones

    Communications Biology · Molecular Neurobiology

    1. Stranded dolphins in Florida showed brain changes strikingly similar to Alzheimer's, providing more evidence that environmental neurotoxins don't stop at humans.

      Communications Biology, 8: 1400
    2. With a single blood draw, your support helped deliver a rapid test that identifies ALS.

      Molecular Neurobiology, 63: 298 (2026)
  13. 2026

    One milestone

    Toxins

    1. New research shows BMAA can travel through the air, far from any lake or reservoir, reshaping how we think about prevention and why this work can't stop now.

      Toxins, 18(7): 309
Section 02Right now
Current project

Getting the ALS test to patients

We are moving forward with getting our ALS test into the hands of patients. It has been validated in a commercial laboratory as a CLIA/CAP laboratory-developed test.

Fund this work
What’s next

Tests for the diseases nobody is testing for

We are working to expand our biomarker tests to other underserved neurodegenerative diseases like Alzheimer's, Parkinson's, PLS (Primary Lateral Sclerosis), frontotemporal dementia and others. You can join us in achieving this goal.

Give online